EarlyFDG PET after Radiotherapy to See Brain Metastases and Radionecrosis
Official title: Interest of Early Dynamic Analysis of [18F]-FDG PET Images in the Differential Diagnosis Between Recurrence and Radionecrosis in Brain Metastases.
Run by Centre Hospitalier Universitaire, Amiens · NCT07632092 · Data updated 2026-11-12
This study tests whether a short FDG-PET scan after radiotherapy can help tell apart radionecrosis from recurring brain metastases in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Status | Recruiting |
| Started | May 18, 2026 |
| Main results expected | November 18, 2028 |
| Study ends | November 18, 2028 |
| Registry record updated | June 8, 2026 |
| Trial ID | NCT07632092 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with brain metastases undergoing radiotherapy and referred for FDG-PET as part of routine care.
✕Probably not a fit
Patients with primary brain tumors or cancers with very low FDG uptake may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the use of a 10-minute [18F]-FDG PET scan performed about 45-60 minutes after tracer injection to help distinguish radionecrosis from tumor recurrence in patients who have brain metastases treated with radiotherapy. Participants are adults referred for FDG-PET as part of their usual care and include those with brain metastases from various cancers, excluding primary brain tumors and cancers with low radiotracer avidity. The imaging is coordinated with standard MRI follow-ups at around 3 months and beyond to improve monitoring decisions. The study aims to see whether the PET information adds clarity beyond MRI when distinguishing treatment-related changes from progression.
Why it matters
Potential benefit: If successful, the PET scan could improve accuracy in distinguishing radionecrosis from recurrence, potentially guiding treatment decisions.
How similar studies have gone: FDG-PET has shown potential in differentiating radionecrosis from recurrence in some brain lesion settings, but this specific short-duration protocol for post-radiotherapy brain metastases is being explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient referred for cerebral \[18F\]-FDG PET examination prescribed as part of his usual medical care for brain metastasis. * Age ≥ 18 years old * Affiliation to a social security program * Ability of the subject to understand and express his consent Exclusion Criteria: * Age under 18 years old * Person under guardianship or curatorship * Pregnant or breastfeeding woman * Primary brain tumors * Brain metastases from renal, thyroid or other cancers known to have low avidity for \[18F\]-FDG
Where it's running
-
CHRU Amiens
Amiens, France Recruiting
Study contacts
- Study coordinator: Antoine GIRARD
- Email: Girard.Antoine@chu-amiens.fr
- Phone: 33+3 22 45 03 81
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment for recurrent brain metastases after radiation therapy
This study is testing whether Laser Interstitial Thermal Therapy or other radiation treatments work better for patients with brain tumors that have come back after previous radiation therapy.
-
Gut microbiome and metabolomics after stereotactic radiosurgery
This study will see if the gut microbiome and blood metabolites change after stereotactic radiosurgery and whether those changes relate to adverse effects like radiation necrosis.
-
IL-8 receptor–modified CAR T cells for brain metastases in adults
This phase 1 study tests whether patient-derived, IL-8 receptor–modified CD70 CAR T cells can be safely given to adults with brain metastases.
-
Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain
This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.
-
Molecular comparison of primary gastroesophageal cancers and their brain metastases
This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.
-
Imaging inflammation in primary and metastatic brain tumors with [C-11]-CS1P1 PET
This trial will test a new PET tracer, [C-11]-CS1P1, in adults with primary or secondary brain tumors to see if tracer patterns of inflammation relate to MRI, treatments, and clinical outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.